Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 99mTc sestamibi Clear all

Conditions: Myocardial Infarction
Interventions: Technetium Tc99m Sestamibi; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Thyroid Cancer
Interventions: 99mTc sestamibi; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions: docetaxel, tariquidar, 99mTc-sestamibi imaging; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease (CAD)
Interventions: regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast, Single Photon Emission Computed Tomography, Multidetector Computed Tomography; Drug · Radiation · Procedure
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Roseville, California • Torrance, California • Miami, Florida + 6 more

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging (MBI), Tc99m sestamibi; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Neoplasm, Renal Mass
Interventions: Computed Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sestamibi; Procedure · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronary Artery Disease
Interventions: low-dose stress MPI SPECT; Other
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis, Tc 99m sestamibi, radiation therapy; Drug · Other · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Carcinoma
Interventions: Digital Breast Tomosynthesis (DBT), Scintimammography; Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 3,023 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 5
States / cities: Detroit, Michigan • Rochester, Minnesota • Toledo, Ohio + 2 more

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older · Female only
Enrollment: 1,638 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: SPECT imaging; Radiation
Lead sponsor: Prem Soman; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Kidney Tumor, Renal Benign Neoplasm, Renal Malignant Tumor
Interventions: Not listed
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Cervical, Ovarian, Lung, Breast, Renal
Interventions: paclitaxel, CBT-1(Registered Trademark), Tc 99m sestamibi; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 45 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Molecular Imaging
Interventions: Meal, Exercise, Sestamibi, Caffeine Tablet, External Heating; Dietary Supplement · Other · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Scintimammography, Technetium Tc-99m Sestamibi; Procedure · Other · Radiation + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 6
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Breast Cancer, Bloody Nipple Discharge
Interventions: Molecular Breast Imaging; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 75 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myocardial Infarction, Ischemic Heart Disease
Interventions: Half-dose of the Tc99-m sestamibi (Cardiolite); Drug
Lead sponsor: Edwin Wu; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease (CAD)
Interventions: regadenoson, overencapsulated caffeine, technetium, placebo; Drug · Radiation
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more

Conditions: Kawasaki Disease
Interventions: Sestamibi; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 29
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Breast Neoplasm
Interventions: Biopsy of Breast, Medical Device Usage and Evaluation, Scintimammography, Technetium Tc-99m Sestamibi; Procedure · Other · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease, Angina Pectoris, Unstable Angina, Acute Coronary Syndrome
Interventions: Coronary Computed Tomography Angiography, Stress Nuclear Myocardial Perfusion Imaging; Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Clinical T1 Renal Mass
Interventions: Preoperative 99mTc-Sestamibi SPECT/CT; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI

99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

Tc99m Sestamibi Molecular Breast Imaging

SPECT/CT for the Characterization of Renal Masses

Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Simultaneous Assessment of FFR and SPECT

New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer

Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors

Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast

Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Molecular Breast Imaging in Patients With a History of Bloody Nipple Discharge

Half-Dose Radiopharmaceutical in Wide Beam Reconstruction

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain

Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma